Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
View Older Stories View More Recent Stories
-
AcuityAds to Participate in Upcoming November 2022 Conferences
-
Boss Energy Ltd (BOE:AU) PT Raised to AUD3.22 at Canaccord Genuity
-
Natera (NTRA) Prices 11.43M Share Follow-on Offering at $35/sh
-
Natera Announces Pricing of Follow-On Offering
-
Privia Health Group (PRVA) Announces 5M Share Secondary Offering by Selling Stockholders
-
Privia Health Announces Secondary Offering
-
Electra Closes US$5.5 Million Public Equity Offering
-
Kelso & Company Acquires DEFINITION 6
-
Vyant Bio Reports Third Quarter 2022 Results and Provides Strategic and Business Highlights
-
Vyant Bio Reports Third Quarter 2022 Results and Provides Strategic and Business Highlights
-
THE VERY GOOD FOOD COMPANY REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
-
electroCore to Participate at Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum
-
electroCore to Participate at Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum
-
Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
-
Canaccord Genuity Downgrades Akumin (AKU) to Spec. Buy
-
Form 8.3 - [REACH PLC 11 11 2022] CGAML (formerly HHL)
-
Form 8.3 - [EMIS GROUP PLC 11 11 2022] - CGWL
-
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
-
Diffusion Pharmaceuticals (DFFN) Reports Significant Progress in its Strategic Review Process
-
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
-
Electric vehicle makers burning cash, slammed by sky-high costs
-
PacBio to Present at Upcoming Investor Conferences
-
Blue Apron (APRN) Enters $30M Equity Distribution Agreement
-
Form 8.3 - [EMIS Group plc - 10 11 2022] - (CGWL)
-
Discovery 2022 Short Duration LP Final Closing November 23, 2022 – Maximum $25,000,000
-
Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference
-
Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference
-
UPDATE: Canaccord Genuity Upgrades Repro Med Systems (KRMD) to Buy
-
UPDATE: Canaccord Genuity Downgrades PARTS iD (ID) to Hold
-
InterVenn Biosciences to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
-
Lucid Diagnostics to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
-
QuoteMedia Announces 15% Revenue Growth for Q3 2022
-
MIMEDX to Present at Upcoming Investor Conferences
-
Triple Flag and Maverix to Combine: Building the Next Senior Precious Metals Streaming and Royalty Company
-
TRIPLE FLAG AND MAVERIX TO COMBINE: BUILDING THE NEXT SENIOR PRECIOUS METALS STREAMING AND ROYALTY COMPANY
-
Cardiovascular Systems, Inc. to Participate in Two November Healthcare Conferences
-
T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
-
Atalaya Mining PLC Announces PDMR Share Dealing
-
DocGo Announces Upcoming Participation in Four Investor Conferences
-
UPDATE: Canaccord Genuity Downgrades Unisys (UIS) to Hold
-
UPDATE: Canaccord Genuity Downgrades Bioventus Inc (BVS) to Hold
-
IsoPlexis to Participate in Upcoming Investor Conferences
-
IsoPlexis to Participate in Upcoming Investor Conferences
-
Today’s important price target changes
-
Today's most important initiations
-
Artivion to Participate in Upcoming Investor Conferences
-
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
-
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
-
Parse Biosciences to Participate in Canaccord Genuity Investor Conference

